DOCSLIB.ORG

Manufacturers with Signed Rebate Agreements October 1 , 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements October 1 , 2010 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00126 COLGATE ORAL PHARMACEUTICAL 1/1/1991 Y 00003 E R SQUIBB AND SONS INC. 1/1/1991 Y 00131 SCHWARZ PHARMA, INC. 1/1/1991 Y 00004 HOFFMANN LAROCHE INC 1/1/1991 Y 00132 C B FLEET COMPANY INC. 1/1/1991 00005 LEDERLE LABORATORIES 1/1/1991 Y 00135 SMITHKLINE BEECHAM 1/1/1995 Y 00006 MERCK SHARP & DOHME 1/1/1991 Y 00143 WEST-WARD PHARMACEUTICAL C 1/1/1991 Y 00007 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00145 STIEFEL LABORATORIES INC. 1/1/1991 Y 00008 WYETH AYERST LABORATORIES 1/1/1991 Y 00149 PROCTER & GAMBLE PHARMACEU 1/1/1991 Y 00009 PHARMACIA AND UPJOHN 1/1/1991 Y 00168 E FOUGERA AND CO, DIV OF ALTAN 1/1/1991 Y 00013 PHARMACIA AND UPJOHN 1/1/1991 Y 00169 NOVO NORDISK PHARMACEUTICAL 1/1/1991 Y 00015 INVAMED, INC 1/1/1991 Y 00172 ZENITH LABORATORIES, INC 1/1/1991 Y 00023 ALLERGAN INC. 1/1/1991 Y 00173 GLAXOSMITHKLINE 1/1/1991 Y 00024 SANOFI SYNTHELABO 1/1/1991 00178 MISSION PHARMACAL COMPANY 1/1/1991 Y 00025 PHARMACIA CORPORATION 1/1/1991 Y 00182 GOLDLINE LABORATORIES INC 1/1/1991 Y 00026 BAYER CORP PHARMACEUTICAL DI 1/1/1991 Y 00185 EON LABS MANUFACTURING, INC. 1/1/1991 Y 00028 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00186 ASTRAZENECA LP 1/1/1991 Y 00029 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00187 ICN PHARMACEUTICALS INC. 1/1/1991 Y 00031 LEDERLE PIPERACILLIN 1/1/1991 Y 00206 ELKINS-SINN 1/1/1991 Y 00032 INTERNATIONAL LABORATORIES 1/1/1991 Y 00212 SANDOZ NUTRITION 1/1/1991 00037 CARTER- WALLACE, INC. 1/1/1991 Y 00224 KONSYL PHARMACEUTICALS, INC. 1/1/1992 00039 HOECHST MARION ROUSSEL INC. 1/1/1991 00225 B F ASHER COMPANY INC., 1/1/1991 00045 MCNEIL PHARMACEUTICAL 1/1/1991 Y 00228 PUREPAC PHARM. CO, DIV KALIPHA 1/1/1991 Y 00046 LEDERLE PARENTERALS 1/1/1991 Y 00245 UPSHER-SMITH LABORATORIES IN 1/1/1991 Y 00049 PFIZER-ROERIG 1/1/1991 Y 00256 FLEMING AND COMPANY 10/1/1991 Y 00051 UNIMED PHARMACEUTICALS, INC 10/1/1997 Y 00258 INWOOD LABORATORIES INC 1/1/1991 Y 00052 ORGANON INC. 1/1/1991 00259 MERZ PHARMACEUTICALS 1/1/1991 00053 AVENTIS BEHRING 1/1/1991 00264 B BRAUN MEDICAL, INC. 1/1/1991 00054 ROXANE LABORATORIES, INC. 1/1/1991 Y 00276 MISEMER PHARMACEUTICAL, INC. 10/1/2006 00056 DU PONT PHARMACEUTICALS 1/1/1991 Y 00277 LASER INC 1/1/1991 Y 00062 ORTHO MCNEIL PHARMACEUTICAL 1/1/1991 Y 00281 SAVAGE LABS, DIV OF ALTANA INC 1/1/1991 Y 00064 HEALTHPOINT LTD 7/1/1995 Y 00288 FLUORITAB CORPORATION 10/1/1991 00065 ALCON LABORATORIES, INC. 1/1/1991 Y 00299 GALDERMA, L.T. 1/1/1991 00066 DERMIK LABORATORIES 1/1/1991 00300 TAP PHARMACEUTICALS INC 1/1/1991 Y 00067 NOVARTIS CONSUMER HEALTH INC 1/1/1991 00310 ASTRAZENECA LP 1/1/1991 Y 00068 HOECHST MARION ROUSSEL INC. 1/1/1991 00327 UNITED GUARDIAN, INC. 1/1/1991 Y 00069 PFIZER INC 1/1/1991 Y 00338 BAXTER HEALTHCARE CORPORATI 1/1/1991 00071 WARNER-LAMBERT 1/1/1991 Y 00378 MYLAN PHARMACEUTICALS, INC. 1/1/1991 Y 00072 APOTHECON INC 1/1/1991 00406 MALLINCKRODT SPECIALTY CHEMI 7/1/1993 Y 00074 ABBOTT LABORATORIES 1/1/1991 Y 00409 HOSPIRA, INC 1/1/2005 00075 RHONE-POULENC RORER PHARMA 1/1/1991 00414 SUPPOSITORIA LABORATORIES 4/1/1994 Y 00078 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00430 WARNER CHILCOTT LABORATORIE 1/1/1998 00083 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00456 FOREST PHARMACEUTICALS INC 1/1/1991 Y 00085 SCHERING PLOUGH PHARMACEUTI 1/1/1991 00462 PHARMADERM 7/1/2003 00087 BRISTOL-MYERS SQUIBB COMPANY 1/1/1991 Y 00469 LYPHOMED DIVISION FUJISAWA US 1/1/1991 Y 00088 HOECHST MARION ROUSSEL, INC. 1/1/1991 00472 ALPHARMA, USPD 1/1/1991 Y 00089 3M PHARMACEUTICALS 1/1/1991 Y 00482 BRADLEY PHARMACEUTICALS, INC. 1/1/1991 Y 00091 KREMERS URBAN CO. 1/1/1991 Y 00485 EDWARDS PHARMACEUTICALS, IN 1/1/1991 Y 00093 TEVA PHARMACEUTICALS 1/1/1991 Y 00486 BEACH PRODUCTS INC 1/1/1991 Y 00095 ECR PHARMACEUTICALS 7/1/1993 Y 00487 NEPHRON PHARMACEUTICALS CO 4/1/1992 Y 00096 PERSON & COVEY INC. 4/1/1999 00496 FERNDALE LABORATORIES INC. 1/1/1991 Y 00113 L. PERRIGO COMPANY 7/1/2003 00517 AMERICAN REGENT LABS, INC. 7/1/1993 00115 GLOBAL PHARMACEUTICAL COMPA 1/1/1991 Y 00525 PAN AMERICAN LABORATORIES IN 1/1/1991 Y 00116 XTTRIUM LABORATORIES, INC 1/1/2002 Y 00527 LANNETT COMPANY INC. 7/1/1994 Y 00121 PHARMACEUTICAL ASSOCIATES, IN 1/1/1991 Y 00535 GILBERT LABORATORIES 7/1/2002 Y Page 1 of 6 N = NEW; D = DELETED; X = COVERED (NO REBATE AGREEMENT); Y=SENIORCARE REBATE AGREEMENT ON FILE Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements October 1 , 2010 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00536 WATSON PHARMA, INC 1/1/1991 Y 11523 SCHERING PLOUGH HEALTHCARE 4/1/2003 00548 INTERNATIONAL MEDICATION SYS 1/1/1991 Y 11528 CENTRIX PHARMACEUTICAL, INC 7/1/2006 Y 00555 BARR LABORATORIES INC 1/1/1991 Y 11530 GLAXOSMITHKLINE 4/1/2002 Y 00573 WYETH AYERST LABORATORIES 1/1/1991 11701 COLOPLAST CORPORATION 10/1/1991 Y 00574 PADDOCK LABORATORIES, INC. 1/1/1991 Y 11980 ALLERGAN INC 1/1/1991 Y 00575 BAKER NORTON PHARMACEUTICAL 1/1/1991 Y 12496 RECKITT & COLMAN PHARMACEUTI 1/1/1994 00590 DU PONT PHARMACEUTICALS 1/1/1991 Y 12593 RED RIIVER PHARMA MANUFACTUR 4/1/2006 00591 WATSON PHARMA, INC 7/1/2001 Y 12830 R.A. MCNEIL 1/1/1991 Y 00597 BOEHRINGER INGELHEIM PHARMA 1/1/1991 Y 12939 MARLOP PHARMACEUTICALS, INC. 1/1/1991 00603 QUALITEST PRODUCTS, INC. 1/1/1991 Y 12948 NITROMED INC 10/1/2005 00615 VANGUARD LABS, INC 1/1/1991 Y 13107 AUROBINDO PHARMA USA, INC 7/1/2005 Y 00641 ESI LEDERLE, INC 1/1/1991 13279 ALLAN PHARMACEUTICALS, LLC 10/1/2005 00642 EVERETT LABORATORIES 1/1/1991 Y 13310 A R SCIENTIFIC, INC 1/1/2006 Y 00677 UNITED RESEARCH LABORATORIE 1/1/1991 Y 13436 VENUS 1/1/2009 00682 MARNEL PHARMACEUTICALS INC 1/1/1991 13453 GRACEWAY PHARMACEUTICALS, L 4/1/2007 Y 00703 GENSIA SICOR PHARMACEUTICALS 7/1/1992 Y 13478 BARRIER THERAPEUTICS 1/1/2006 00713 G AND W LABORATORIES INC 1/1/1991 Y 13533 TALECRIS BIOTHERAPEUTICS, INC 10/1/2005 00777 DISTA PRODS CO DIV OF ELI LILLY 1/1/1991 Y 13548 CORIA LABORATORIES, LTD 4/1/2006 00781 GENEVA PHARMACEUTICALS, INC., 1/1/1991 Y 13551 FSC LABORATORIES, INC 1/1/2006 00785 UAD LABORATORIES INC 1/1/1991 Y 13632 ROSEMONT PHARMACEUTICALS LT 7/1/2007 00813 PHARMICS INC. 1/1/1991 13668 TORRENT PHARM, INC. 10/1/2007 Y 00832 USL PHARMA, INC 1/1/1991 Y 13811 TRIGEN LABORATORIES, INC. 4/1/2006 00884 PEDINOL PHARMACAL INC 1/1/1991 Y 13845 DBA THE CHAO CENTER 4/30/2009 00904 MAJOR PHARMACEUTICALS 1/1/1991 Y 13913 DEPOMED, INC 10/1/2005 00941 BAXTER HEALTHCARE CORP. 4/1/2010 13925 SETON PHARMACEUTICALS, LLC 11/18/2008 00944 BAXTER BIOTECH 1/1/1991 14168 STONEBRIDGE PHARMA , LLC 1/1/2007 Y 00955 SANOFI SYNTHELABO 1/1/1996 14508 SUN PHARMACEUTICAL INDUSTRIE 7/1/2006 Y 00998 ALCON -PUERTO RICO- INC. 1/1/1991 Y 14550 ACTAVIS PHARMA MFGING PRIVAT 4/27/2010 Y 08880 KENDALL HEALTHCARE PRODUCTS 1/1/1991 15054 TERCICA, INC 4/1/2006 08884 SHERWOOD MEDICAL 1/1/1991 15127 SELECT BRAND DISTRIBUTORS 10/1/2006 10019 BAXTER HEALTHCARE CORPORATI 10/1/2001 15210 OTN GENERICS, INC. 10/1/2006 10122 CORNERSTONE BIOPHARM, INC 7/1/2005 15330 GENPHARM, L.P. 4/1/2006 Y 10139 GENERALMEDIX, INC. 12/9/2008 15338 APACE KY, LLC 1/1/2009 Y 10144 ACORDA THERAPEUTICS, INC 10/1/2005 15370 CARWIN ASSOCIATES, INC. 10/1/2006 Y 10147 PATRIOT PHARMACEUTICALS, LLC 4/1/2005 Y 15456 ESPRIT PHARMA, INC. 4/1/2006 Y 10148 COTHERIX, INC 7/1/2005 15584 BRISTOL-MYERS SQUIBB & GILEAD 7/1/2006 Y 10158 GLAXOSMITHKLINE 4/1/2002 Y 15686 MIDLAND HEALTHCARE, LLC 4/1/2006 10267 CONTRACT PHARMACAL CORP 1/1/1991 Y 15821 FOCUS LABORATORIES, INC. 10/1/2006 10337 DOAK DERMATOLOGICS DIV 7/1/2002 Y 16103 PHARBEST PHARMACEUTICALS, IN 10/1/2006 10370 ANCHEN PHARMACEUTICALSINC 7/1/2007 16252 COBALT LABORATORIES, INC 10/1/2006 Y 10454 SOLSTICE NEUROSCIENCES, INC 1/1/2006 16477 LASER PHARMACEUTICALS, LLC 7/1/2006 Y 10542 HILLESTAD INTERNATIONAL, INC. 4/1/1994 Y 16571 PACK PHARMACEUTICALS, L.L.C. 4/1/2006 Y 10572 AFFORDABLE PHARMACEUTICALS, 1/1/2005 Y 16714 NORTHSTAR RX, LLC 4/1/2008 Y 10631 RANBAXY LABORATORIES INCORP 10/1/2005 16729 ACCORD HEALTHCARE INC. 7/1/2008 Y 10702 KVK TECH INC 1/1/2007 Y 16781 ONSET THERAPEUTICS 7/1/2006 10768 PERRIGO PHARMACEUTICALS CO 4/1/2005 16887 VERNALIS PHARMACEUTICALS INC 10/1/2006 10892 LUNSCO INC 1/1/1991 Y 17314 ALZA CORPORATION 1/1/1991 Y 10914 BRIGHTON PHARMACEUTICALS, IN 1/1/2006 17433 ENEMEEZ INC 4/1/2007 Y 10922 INTENDIS, INC 10/1/2005 17478 AKORN INC 1/1/1991 Y 11042 ADVANCIS PHARMACEUTICAL 1/1/2006 18011 ZERIS PHARMA, LLC.
Recommended publications
  • 2009: Turning the Corner

    2009: Turning the Corner

    data page 2009: Turning the corner Walter Yang Despite the shaky start to 2009, the biotech sector regained its financial Although initial public offerings showed signs of resuscitation (at least footing. Biotech indices were up, as were offerings and partnership mon- 13 more companies are now in the queue), follow-on financings came in ies. Excluding collaborations, the sector raised a total of $24.3 billion. above $6 billion—the second-best year over the past decade. Stock market performance Global biotech industry financing Although biotech indices were up ~16% last year, they underperformed The boost in partnership promises to US biotechs and follow-on financings other major indices. pushed industry funding to $61.3 billion, up 82% from 2008. 1,500 Swiss Market S&P 500 2009 36.9 10.0 5.1 2.2 6.0 0.9 1,400 NASDAQ Biotech Dow Jones 2008 20.0 3.2 5.3 3.1 1.9 0.1 1,300 NASDAQ BioCentury 100 2007 22.4 11.7 6.8 4.7 4.4 3.0 1,200 Partnering 2006 19.8 11.9 5.6 4.7 5.6 2.0 1,100 Year Debt and other Index 17.3 6.1 5.4 2.7 4.8 1.9 1,000 2005 Venture capital PIPEs 900 2004 10.9 8.8 5.3 2.9 3.3 2.6 Follow-ons 800 2003 8.9 9.1 4.0 2.2 3.9 0.5 IPOs 700 010203040506070 Amount raised ($ billions) 1/09 2/09 3/09 4/09 5/09 6/09 7/09 8/09 9/09 12/08 Month ending 10/09 11/09 12/09 Partnership figures are for deals involving a US company.
  • Transcept Pharmaceuticals, Inc

    Transcept Pharmaceuticals, Inc

    Table of Contents SCHEDULE 14A (RULE 14A 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by x Definitive Proxy Statement Rule 14a-6(e)(2)) ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 Transcept Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents NOTICE OF ANNUAL MEETING OF STOCKHOLDERS JUNE 23, 2011 To Our Stockholders: NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of Transcept Pharmaceuticals, Inc., a Delaware corporation, will be held on Thursday, June 23, 2011, at 8:30 a.m., local time, at our office located at 1003 West Cutting Blvd., Suite 110, Point Richmond, California 94804, for the following purposes: 1.
  • Manufacturers and Wholesalers Street

    Manufacturers and Wholesalers Street

    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
  • Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products

    Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products

    OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Saralisa C. Brau Deputy Assistant Director September 2009 TABLE OF CONTENTS Page I. INTRODUCTION. ........................................................... 1 II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS. 3 A. Monopolization. ...................................................... 3 B. Agreements Not to Compete. ............................................ 8 C. Agreements on Price or Price-Related Terms. 14 D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing. 20 E. Illegal Tying and Other Arrangements. .................................... 20 III. PHARMACEUTICAL MERGERS. ........................................... 20 A. Horizontal Mergers Between Direct Competitors. 20 B. Potential Competition Mergers. ......................................... 44 C. Innovation Market Mergers. ............................................ 47 D. Vertical Mergers...................................................... 49 IV. INDUSTRY GUIDANCE STATEMENTS...................................... 50 A. Advisory Opinions. ................................................... 50 B. Citizen Petition to the Food and Drug Administration. 51 V. AMICUS BRIEFS. ......................................................... 51 VI. INDICES. ............................................................
  • Chrysler Affiliate Rewards Program

    Chrysler Affiliate Rewards Program

    Chrysler Affiliate Rewards Program If you or your spouse work, or have retired from, one of the companies listed below, you may qualify for pricing as low as 1% Below Factory Invoice on a New FIAT! Check the list of companies below to see if your company qualifies.* A F O AAA-- State of Ohio Members Freightliner Of Tampa, Llc Ocala Freightliner ABB, Inc. Freightliner Of Toledo OCE'- North America Abbott Labs Freightliner Of Utah, Llc Ocean Freightliner, Ltd. Abbott, Nicholson, Quilter, Freightliner Trucks So. Florida Inc. O'connor Gmc, Inc. Esshaki & Youngblood PC Freightliner Twin Ports O'connor Truck Sales, Inc. Abercrombie & Fitch Freightmasters Ohio Machinery Company AboveNet Fresenius Medical dba Ohio CAT Abraxis Bioscience Inc. Fresno Truck Center Oklahoma City Freightliner Accor North America FRIENDLY MOTORCARS Oklahoma Farm Bureau Ace Hardware Corporation Fru-Con Construction Corporation Oklahoma Publishing Company, Action Western Star Fujisawa Healthcare Inc. The (OPUBCO) Actelion Pharmaceuticals US, Inc. Ftl And Ws Of Maine Old Dominion Freight Lines Action Couriers Ftl And Wst Of Tifton Oldcastle Inc. ADVANTAGE Health Solutions, Inc. Ftl Stl Wst Of Odessa Omaha Truck Center Inc Advance Publications Ftl Trucks Of South Florida Omni Care Health Plan Aearo Company Ftl, Stl And Wst Of Montgomery One Call Locators Aetna Ftl,Stl, and Western Star Of Dothan One Source Management Inc Affinia Group Fyda Freightliner Cincinnati Oracle Corporation Agar Truck Sales, Inc. Fyda Freightliner Columbus,Inc Organon Pharmaceuticals USA, Inc. AGCO Corporation Fyda Freightliner Pittsburgh Orlando Freightliner AGFA Corporation Fyda Freightliner Youngstown Orlando Freightliner South Aggreko, LLC ORRIN B HAYES, INC. Agricredit Acceptance LLC G Oscient Pharmaceuticals Agrilink Foods OSI Pharmaceuticals Gabrielli Ford Truck Sales AGSTAR Financial Services Otjen, Van Ert, Stangle, Lieb & Weir, S.C.
  • Manufacturers with Signed Rebate Agreements February 1 , 2011

    Manufacturers with Signed Rebate Agreements February 1 , 2011

    Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements February 1 , 2011 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00126 COLGATE ORAL PHARMACEUTICAL 1/1/1991 Y 00003 E R SQUIBB AND SONS INC. 1/1/1991 Y 00131 SCHWARZ PHARMA, INC. 1/1/1991 Y 00004 HOFFMANN LAROCHE INC 1/1/1991 00132 C B FLEET COMPANY INC. 1/1/1991 00005 LEDERLE LABORATORIES 1/1/1991 Y 00135 SMITHKLINE BEECHAM 1/1/1995 Y 00006 MERCK SHARP & DOHME 1/1/1991 Y 00143 WEST-WARD PHARMACEUTICAL C 1/1/1991 Y 00007 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00145 STIEFEL LABORATORIES INC. 1/1/1991 Y 00008 WYETH AYERST LABORATORIES 1/1/1991 Y 00149 PROCTER & GAMBLE PHARMACEU 1/1/1991 Y 00009 PHARMACIA AND UPJOHN 1/1/1991 Y 00168 E FOUGERA AND CO, DIV OF ALTAN 1/1/1991 Y 00013 PHARMACIA AND UPJOHN 1/1/1991 Y 00169 NOVO NORDISK PHARMACEUTICAL 1/1/1991 Y 00015 INVAMED, INC 1/1/1991 Y 00172 ZENITH LABORATORIES, INC 1/1/1991 Y 00023 ALLERGAN INC. 1/1/1991 Y 00173 GLAXOSMITHKLINE 1/1/1991 Y 00024 SANOFI SYNTHELABO 1/1/1991 Y 00178 MISSION PHARMACAL COMPANY 1/1/1991 Y 00025 PHARMACIA CORPORATION 1/1/1991 Y 00182 GOLDLINE LABORATORIES INC 1/1/1991 Y 00026 BAYER CORP PHARMACEUTICAL DI 1/1/1991 Y 00185 EON LABS MANUFACTURING, INC. 1/1/1991 Y 00028 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00186 ASTRAZENECA LP 1/1/1991 Y 00029 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00187 ICN PHARMACEUTICALS INC.
  • CONCERT PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)

    CONCERT PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material under §240.14a-12 CONCERT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 1 Concert Pharmaceuticals, Inc.
  • The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry

    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry

    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field.
  • 28 May 2009 Thomas E. Costa

    28 May 2009 Thomas E. Costa

    The Third International Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Thomas E. Costa 2828 MayMay 20092009 This presentation represents my own personal opinion and is not the official position of Bristol-Myers Squibb PhRMA Code 2009 • Updated in response to concerns of healthcare stakeholders • Reaffirms that interactions between pharmaceutical company representatives and healthcare professionals (HCPs) should: ¾ Inform HCPs about the benefits and risks of our products ¾ Provide scientific and educational information ¾ Obtain feedback and advice about our products through consultation with medical experts • The PhRMA Code is the new industry standard PhRMA Code Signatory Companies • Abbott • Eli Lilly and Company • Amgen, Inc. • Merck & Company, Inc. • Amylin Pharmaceuticals, Inc. • Millennium Pharmaceuticals, Inc. • Astellas US LLC • Novartis Pharmaceuticals • AstraZeneca LP Corporation • Bayer HealthCare • Novo Nordisk Inc. Pharmaceuticals • Otsuka America, Inc. • Boehringer Ingleheim • Ovation Pharmaceuticals, Inc. Pharmaceuticals, Inc. • Pfizer, Inc. • Bristol-Myers Squibb Company • Purdue Pharma LP • Cephalon, Inc. • sanofi-aventis US • Covidien Ltd. • Schering-Plough Corporation • Daiichi Sankyo, Inc. • Sepracor, Inc. • Eisai, Inc. • Signa-Tau Pharmaceuticals, Inc. • EMD Serono • Solstice Neurosciences, Inc. • Endo Pharmaceuticals, Inc. • Solvay Pharmaceuticals, Inc. • Genzyme Corporation • Takeda Pharmaceuticals North • GlaxoSmithKline America, Inc. • Hoffmann-La Roche, Inc. • Wyeth • Johnson and Johnson
  • Management Liability Focus Johnson & Johnson 1

    Management Liability Focus Johnson & Johnson 1

    Insured Profile Report – Management Liability Focus Johnson_________________________________________________________________________ & Johnson Company Profile Credit Details Location 1 Johnson and Johnson Plz Overall Credit Risk High Risk New Brunswick, NJ www.jnj.com Number of Legal Derogatory 84 Company Type Public Items Liability Amount $322,285.00 Formerly Known As N/A Experian Intelliscore 2.57 SIC Code 2834 SIC Code Description Pharmaceutical Preparations Experian Intelliscore Percentile 2.00 % of companies score lower and have higher credit risk Established 1955 Experian Commercial IntelliscoreSM is an all-industry commercial model using business information to predict business risk. Its Sales (in millions) $65,030.00 predictiveness is among the best on the market today The objective of the Commercial Intelliscore Model is to predict seriously Employees 117,900 derogatory payment behavior. Possible score range from 0 to 100, where 0 is high risk and 100 is low risk Total OSHA Violations 18 -Liability Amount is the total dollar amount of debtor’s legal liability, OSHA is an arm of the Department of Labor that conducts inspections of company including accounts in collection, tax liens,judgments and/or bankruptcies facilities with the goal of preventing work-related injuries, illnesses and deaths. -The Number of Legal Derogatory items are the sum of Tax-Lien Worksites that do not meet health and/or safety standards at the time of inspection may Count, Bankruptcy,Judgment, Collection-Counter and UCC Derog receive an OSHA violation. Total FDA NDC Drugs 177 The total number of FDA Drugs filed in the FDA NDC Drug Database. Business Description Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field.
  • ANTARES PHARMA, INC. 100 Princeton South, Suite 300 Ewing, New Jersey 08628 April 27, 2020 Dear Stockholder: You Are Cordially I

    ANTARES PHARMA, INC. 100 Princeton South, Suite 300 Ewing, New Jersey 08628 April 27, 2020 Dear Stockholder: You Are Cordially I

    ANTARES PHARMA, INC. 100 Princeton South, Suite 300 Ewing, New Jersey 08628 April 27, 2020 Dear Stockholder: You are cordially invited to attend the 2020 Annual Meeting of Stockholders of Antares Pharma, Inc. (the “Company”), to be held at 10:00 a.m., Eastern Time, on Thursday, June 11, 2020 virtually via the Internet at www.virtualshareholdermeeting.com/ATRS2020 (the “Annual Meeting”). For the first time, our annual meeting will be a “virtual meeting” of stockholders, which will be conducted exclusively via the Internet through a virtual web conference. There will not be a physical meeting location, and stockholders will not be able to attend the annual meeting in person. Instructions on how to participate in the Annual Meeting and demonstrate proof of stock ownership are posted at www.virtualshareholdermeeting.com/ATRS2020. This means that you can attend the annual meeting online, vote your shares electronically and submit questions during the online meeting by visiting the above-mentioned website. We believe that hosting a “virtual meeting” will enable greater stockholder attendance and participation from any location around the world. In addition, in response to continued public health concerns related to COVID-19 and group gatherings, we also believe holding a “virtual meeting” will help ensure the health and well-being of our stockholders and other meeting participants. The notice of the 2020 Annual Meeting of Stockholders and the proxy statement that appear on the following pages describe the matters scheduled to come before the meeting. In addition, certain members of our Board of Directors and management team, as well as representatives of KPMG LLP, our independent registered public accounting firm, will be available to answer appropriate questions.
  • Why Are Some Generic Drugs Skyrocketing in Price? Hearing Committee on Health, Education, Labor, and Pensions United States Sena

    Why Are Some Generic Drugs Skyrocketing in Price? Hearing Committee on Health, Education, Labor, and Pensions United States Sena

    S. HRG. 113–859 WHY ARE SOME GENERIC DRUGS SKYROCKETING IN PRICE? HEARING BEFORE THE SUBCOMMITTEE ON PRIMARY HEALTH AND AGING OF THE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS UNITED STATES SENATE ONE HUNDRED THIRTEENTH CONGRESS SECOND SESSION ON EXAMINING THE PRICING OF GENERIC DRUGS NOVEMBER 20, 2014 Printed for the use of the Committee on Health, Education, Labor, and Pensions ( Available via the World Wide Web: http://www.gpo.gov/fdsys/ U.S. GOVERNMENT PUBLISHING OFFICE 24–459 PDF WASHINGTON : 2017 For sale by the Superintendent of Documents, U.S. Government Publishing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2104 Mail: Stop IDCC, Washington, DC 20402–0001 VerDate Nov 24 2008 13:32 May 19, 2017 Jkt 000000 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 S:\DOCS\24459.TXT DENISE HELPN-003 with DISTILLER COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS TOM HARKIN, Iowa, Chairman BARBARA A. MIKULSKI, Maryland LAMAR ALEXANDER, Tennessee PATTY MURRAY, Washington MICHAEL B. ENZI, Wyoming BERNARD SANDERS (I), Vermont RICHARD BURR, North Carolina ROBERT P. CASEY, JR., Pennsylvania JOHNNY ISAKSON, Georgia KAY R. HAGAN, North Carolina RAND PAUL, Kentucky AL FRANKEN, Minnesota ORRIN G. HATCH, Utah MICHAEL F. BENNET, Colorado PAT ROBERTS, Kansas SHELDON WHITEHOUSE, Rhode Island LISA MURKOWSKI, Alaska TAMMY BALDWIN, Wisconsin MARK KIRK, Illinois CHRISTOPHER S. MURPHY, Connecticut TIM SCOTT, South Carolina ELIZABETH WARREN, Massachusetts DEREK MILLER, Staff Director LAUREN MCFERRAN, Deputy Staff Director and Chief Counsel DAVID P. CLEARY, Republican Staff Director SUBCOMMITTEE ON PRIMARY HEALTH AND AGING BERNARD SANDERS, Vermont, Chairman BARBARA A.